Dossier assessment
Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection
Advantage in overall survival and recurrence, disadvantages in side effects; indication of considerable added benefit
Press releases
Melanoma: dabrafenib and trametinib have added benefit
Additional information
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.
Project details
- Project no.
- A18-59
- Commission
- Commission awarded on 24.09.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Dabrafenib (high-grade malignant glioma in paediatric patients aged 1 year and older, in combination with trametinib) – Assessment according to §35a SGB V (1), Sentence 11
Status: Commission completed